AWI-Gen Phase 2: Genomic and environmental risk factors for cardiometabolic disease in Africans

AWI-Gen 第 2 期:非洲人心脏代谢疾病的基因组和环境危险因素

基本信息

项目摘要

AWI-Gen Phase 2 - Overall component Abstract AWI-Gen is the Africa Wits-INDEPTH partnership for Genomic Studies, a NIH funded and university supported Collaborative Center of the Human Heredity and Health in Africa (H3Africa) Consortium. It is a strategic partnership between the University of the Witwatersrand, Johannesburg (Wits), and the International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH). AWI-Gen examines genomic and environmental factors that interact with individual physiology and behaviors to influence body composition, body fat distribution and cardiometabolic disease and risk in African populations, with the aim to provide insights and evidence toward effective prevention, treatment and intervention strategies. Empirical, validated African data to inform modeling, projections and policy remain scant and widening health inequalities are evident within and between countries, despite global improvements in age-standardized mortality and morbidity. AWI-Gen Phase 1 is a population-based cross-sectional study with a research platform of over 12,045 participants 40-60 years from Burkina Faso, Ghana, Kenya and South Africa that addresses these disparities. Our four-year partnership has successfully generated epi-demographic, environmental, health history, behavioral, anthropometric, physiological and genetic data across a range of rapidly transitioning African settings. The AWI-Gen Collaborative Center provides a unique resource to examine genetic associations and gene- environment interactions that will contribute to Afrocentric risk prediction models and African-appropriate Mendelian Randomization instruments, and exploit their potential to improve personal and population health – while strengthening regional research capacity. Our overall goal is to establish the genomic contribution to cardiometabolic disease and risk at a time when multiple interacting transitions, in the presence of high background HIV or malaria prevalence, are driving a rapid escalation in CMD across the African continent. To deepen our understanding of CMD and risk in African populations, we aim to extend data collection and develop a population-based `super' cohort (from harmonized cohorts across geographic settings) that is well-suited to examining progression among middle-aged and older persons. We have developed four closely linked research projects: (1) Genetic association studies to elucidate functional pathways involved in determining body composition and risk for CMD by detecting pivotal genomic and environmental contributors. (2) Building an analytic resource of bioinformatics analysis tools appropriate for African populations, including genetic risk determination, Mendelian Randomization instruments and gene-environment interaction algorithms. (3) Examining changes over the menopausal transition in body composition and CMD risk factors, and evaluating the resulting risk from physiological, genetic and epigenetic perspectives. (4) Examining the microbiome in older adults and its relationship to obesity, diabetes and glucose tolerance, and CMD risks arising from the menopausal transition. We hypothesize that there are African-specific gene-environment interactions that are key drivers of the health transitions unfolding across the continent, and that environmentally influenced epigenetic and microbiome changes play an important role. HIV and malaria will be considered in our models as they may have critical influences. Our emphasis on women in AWI-Gen Phase 2 is informed by the increasing prevalence of obesity and associated morbidities in women, especially in regions farther along an epidemiological transition path. Genomic research in Africa has the unique potential to harness the lower levels of linkage disequilibrium in African genomes for fine mapping of associated loci to identify causal genes and variants, and guide functional analysis in candidate regions. Our first project provides the foundation for the development of cohorts in west- east-south Africa to examine the distinct and interacting influences of genetic variation, environmental, social and demographic factors, personal behaviors, and proximal risk factors on body composition and susceptibility to CMD. This will be the first multi-ethnic study in sub-Saharan Africa to address a critical shortfall in understanding at a time when the force of transitions is driving the rise in cardiometabolic conditions. We expect findings to be highly relevant in our continental context and to contribute insights far more widely.
AWI -GEN第2阶段 - 整体组件 抽象的 Awi-Gen是非洲Wits-Stepth基因组研究的伙伴关系,是NIH资助和大学 支持非洲人类遗传与健康的协作中心(H3africa)财团。是一个 威特沃特斯兰大学,约翰内斯堡(WITS)和国际的战略伙伴关系 人群评估人口及其健康的网络(Indepth)。 AWI-GEN考试 与个体生理学和行为相互作用的基因组和环境因素 身体成分,体内脂肪分布和心脏代谢疾病以及非洲人口的风险, 旨在提供有效预防,治疗和干预策略的见解和证据。 经验,经过验证的非洲数据,以告知建模,项目和政策仍然很少并扩大健康 不平等是国家内部和国家之间的证据,目的地全球改善了年龄标准化的死亡率 和发病率。 Awi-Gen阶段1是一项基于人群的横断面研究 12,045名参与者来自布基纳法索,加纳,肯尼亚和南非40 - 60年 差异。我们的四年合作伙伴关系成功地产生了Epi人口统计学,环境,健康 在一系列快速过渡的非洲人的历史,行为,人体测量学,身体和遗传数据 设置。 AWI-GEN协作中心提供了一种独特的资源来检查遗传关联和基因 环境互动将有助于以非洲为中心的风险预测模型和适合非洲的环境 孟德尔随机仪器,并利用其潜力来改善个人和人口 健康 - 同时增强了区域研究能力。 我们的总体目标是建立对心脏代谢疾病和风险的基因组贡献 当多个相互作用的过渡(在高背景HIV或疟疾患病率的存在下)是 在整个非洲大陆的CMD中迅速升级。加深我们对CMD和 非洲人口的风险,我们旨在扩展数据收集并开发基于人群的“超级”队列(来自 跨地理环境的协调组)非常适合研究中年的发展 和老年人。我们已经开发了四个密切相关的研究项目:(1)遗传关联研究与 通过检测关键来确定身体组成和CMD风险涉及的功能途径 基因组和环境贡献者。 (2)建立生物信息学分析工具的分析资源 适合非洲人口,包括遗传风险确定,孟德尔随机工具 和基因 - 环境相互作用算法。 (3)检查身体更年期过渡的变化 组成和CMD风险因素,并评估物理,遗传和表观遗传学的风险 观点。 (4)检查老年人的微生物组及其与肥胖,糖尿病和葡萄糖的关系 耐受性和CMD风险由更年期过渡引起。 我们假设存在非洲特定的基因环境相互作用,这是 整个非洲大陆的健康转变,环境影响了表观遗传和 微生物组变化起着重要作用。艾滋病毒和疟疾将在我们的模型中考虑 有关键的影响。我们对AWI-GEN第2阶段中女性的重视是由于越来越多的流行而引起的 妇女的肥胖和相关病毒性,尤其是在流行病学转变的地区 小路。非洲的基因组研究具有利用较低链接dissequibrium的独特潜力 在非洲基因组中,用于鉴定因果基因和变异的相关局部的精细映射,并引导功能 候选区域的分析。我们的第一个项目为West- 东南非洲检查遗传变异,环境,社会的独特和相互作用的影响 以及人体组成和易感性的人口因素,个人行为和近端风险因素 到CMD。这将是撒哈拉以南非洲的首次多民族研究,以解决严重的短缺 在过渡力推动心脏代谢条件下增加的时期。 我们希望发现在我们的持续内容中具有很高的相关性,并能够贡献更多的见解 广泛。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Michele Michele Ra...的其他基金

AWI-Gen Phase 2: Genomic and environmental risk factors for cardiometabolic disease in Africans
AWI-Gen 第 2 期:非洲人心脏代谢疾病的基因组和环境危险因素
  • 批准号:
    10405680
    10405680
  • 财政年份:
    2021
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Childhood Status Epilepticus and Epilepsy Determinants of Outcome (SEED)
儿童期癫痫持续状态和癫痫结果决定因素 (SEED)
  • 批准号:
    10222800
    10222800
  • 财政年份:
    2020
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Childhood Status Epilepticus and Epilepsy Determinants of Outcome (SEED)
儿童期癫痫持续状态和癫痫结果决定因素 (SEED)
  • 批准号:
    10378697
    10378697
  • 财政年份:
    2020
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Childhood Status Epilepticus and Epilepsy Determinants of Outcome (SEED)
儿童期癫痫持续状态和癫痫结果决定因素 (SEED)
  • 批准号:
    10595075
    10595075
  • 财政年份:
    2020
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Core D: Biomarkers and Biobanking Core
核心 D:生物标志物和生物样本库核心
  • 批准号:
    10188354
    10188354
  • 财政年份:
    2013
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Core C - Biomarker and Biobanking Core
核心 C - 生物标志物和生物样本库核心
  • 批准号:
    10627331
    10627331
  • 财政年份:
    2013
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Genomic and environmental risk factors for cardiometabolic disease in Africans
非洲人心脏代谢疾病的基因组和环境危险因素
  • 批准号:
    8914169
    8914169
  • 财政年份:
    2012
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Genomic and environmental risk factors for cardiometabolic disease in Africans
非洲人心脏代谢疾病的基因组和环境危险因素
  • 批准号:
    9119535
    9119535
  • 财政年份:
    2012
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Genomic and environmental risk factors for cardiometabolic disease in Africans
非洲人心脏代谢疾病的基因组和环境危险因素
  • 批准号:
    8530163
    8530163
  • 财政年份:
    2012
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Genomic and environmental risk factors for cardiometabolic disease in Africans
非洲人心脏代谢疾病的基因组和环境危险因素
  • 批准号:
    8784175
    8784175
  • 财政年份:
    2012
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:

相似国自然基金

烯丙基叠氮动态平衡混合物的动态动力学拆分
  • 批准号:
    22371245
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
诱导契合金属有机框架分离C3轻烃混合物
  • 批准号:
    22301102
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
非均匀混合物等效辐射不透明度模型的理论研究
  • 批准号:
    12374259
  • 批准年份:
    2023
  • 资助金额:
    52.00 万元
  • 项目类别:
    面上项目
高黏度不挥发组分在混合物气泡生长及脱离过程中的扩散行为及非平衡效应
  • 批准号:
    52376001
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
氢气及其混合物与涡流管耦合特性底层机制及氢能系统性能优化策略研究
  • 批准号:
    52376212
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目

相似海外基金

Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimer’s disease in Ancestral and Admixed Populations
SARS-CoV-2 感染和遗传变异的相互作用对祖先和混血人群认知能力下降和阿尔茨海默病风险的影响
  • 批准号:
    10628505
    10628505
  • 财政年份:
    2023
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
A comprehensive whole genome sequence scan for positive selection in southern Africa
对南部非洲进行全面的全基因组序列扫描以进行正选择
  • 批准号:
    10732789
    10732789
  • 财政年份:
    2023
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP)
ADSP 中阿尔茨海默病多样性遗传群体的招募和保留 (READD-ADSP)
  • 批准号:
    10654529
    10654529
  • 财政年份:
    2022
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
The Study of Muscle and Physical Performance in African Caribbeans.
非洲加勒比海地区肌肉和身体表现的研究。
  • 批准号:
    10598636
    10598636
  • 财政年份:
    2022
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别:
The Study of Muscle and Physical Performance in African Caribbeans.
非洲加勒比海地区肌肉和身体表现的研究。
  • 批准号:
    10337382
    10337382
  • 财政年份:
    2022
  • 资助金额:
    $ 118万
    $ 118万
  • 项目类别: